1 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
Follow Placebo of IN10018: new trials by email Literature Review of Placebo of IN10018 trials Research Report on Placebo of IN10018
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer IN10018, Placebo of IN10018, Pegylated Liposomal Doxorubicin - Ovarian Cancer Recurrent | Phase 2 | Recruiting | InxMed (Shanghai) Co., Ltd. | 168 | 2022-09-06 | 2025-04-30 |
InxMed (Shanghai) Co., Ltd. (1)
China (1)
Lingying WU (1)